BioSpace News Archive

Atomwise Inc., a leader in artificial intelligence (AI) for drug discovery, and Atropos Therapeutics, Inc., a senescence platform discovery company, announced today that they will launch a joint venture company to discover and advance a pipeline of compounds for promising discovery targets for the treatment of cancer.

The FDA confirmed that the review will have an action date of late April, 2020.

Sensorion has contributed three presentations at the 56th Workshop on Inner Ear Biology (IEB 2019) held in Padua, the 7-10th of September, 2019.

According to Morgan Stanley Capital International’s latest set of ESG ratings, 3SBio has been upgraded to BBB status, surpassing that of 61% of companies in the global biotechnology industry.

Merck KGaA, Darmstadt, Germany, announced that the US Food and Drug Administration has granted Breakthrough Therapy Designation for the investigational targeted therapy tepotinib* in patients with metastatic non-small cell lung cancer harboring MET exon 14 skipping alterations who progressed following platinum-based cancer therapy.

Program creates incubator for developing cutting-edge workflow innovations leveraging Epic EMR

United Therapeutics Corporation announced that the U.S. Food and Drug Administration has accepted for review the New Drug Application for Trevyent® for the treatment of pulmonary arterial hypertension.

Most Advanced s-Scanning Near-field Optical Microscopy/Atomic Force Microscopy-IR System Commercially Available

Goal is to increase access to complex medications to ensure patients get the right drug at the right time faster

Dr. Reddy’s Laboratories Ltd. announced the launch of Fosaprepitant for Injection, the therapeutic generic equivalent of EMEND® (fosaprepitant) for injection, approved by the U.S. Food and Drug Administration (USFDA).